Recent findings indicate that PRMT6 facilitates CRC advancement by activating MYC signaling, whereas increased MYC activity and epithelial-mesenchymal transition (EMT) pathways may further intensify CRC malignancy (51, 52). This evidence concerns the gene PRMT6 and colorectal carcinoma.